Abstract
Chronic GVHD (cGVHD) is an important complication of allogeneic hematopoietic cell transplantation (HCT). As preemptive therapy might be efficacious if administered early post transplant, we set out to determine whether cGVHD can be predicted from the serum level of a biomarker on day 7 or 28. In a discovery cohort of 153 HCT recipients conditioned with BU, fludarabine and rabbit antithymocyte globulin (ATG), we determined serum levels of B-cell-activating factor, vascular endothelial growth factor, soluble TNF-α receptor 1, soluble IL2 receptor α, IL5, IL6, IL7, IL15, γ-glutamyl transpeptidase, cholinesterase, total protein, urea and ATG. Patients with low levels of IL15 (<30.6 ng/L) on day 7 had 2.7-fold higher likelihood of developing significant cGVHD (needing systemic immunosuppressive therapy) than patients with higher IL15 levels (P<0.001). This was validated in a validation cohort of 105 similarly-treated patients; those with low IL15 levels had 3.7-fold higher likelihood of developing significant cGVHD (P=0.001). Low IL15 was not associated with relapse; it trended to be associated with acute GVHD and was associated with low infection rates. In conclusion, low IL15 levels on day 7 are predictive of cGVHD, and thus could be useful in guiding preemptive therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Pavletic SZ, Vogelsang GB . Chronic graft-vs-host disease: clinical manifestations and therapy. In: Appelbaum FR, Forman SJ, Negrin RS, Blume KG (eds). Thomas’ Hematopoietic Cell Transplantation. Blackwell Publishing, 2009 pp 1304–1324.
Socie G, Ritz J, Martin PJ . Current challenges in chronic graft-versus-host disease. Biol Blood Marrow Transplant 2010; 16 (1 Suppl): S146–S151.
Shlomchik WD . Graft-versus-host disease. Nat Rev Immunol 2007; 7: 340–352.
Martin PJ, Pavletic SZ . Biology and management of chronic graft-versus-host disease. Cancer Treat Res 2009; 144: 277–298.
Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204–217.
Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945–956.
Inamoto Y, Flowers ME . Treatment of chronic graft-versus-host disease in 2011. Curr Opin Hematol 2011; 18: 414–420.
Lee SJ . Have we made progress in the management of chronic graft-vs-host disease? Best Pract Res Clin Haematol 2010; 23: 529–535.
Holler E . Risk assessment in haematopoietic stem cell transplantation: GvHD prevention and treatment. Best Pract Res Clin Haematol 2007; 20: 281–294.
Marsh JC, Gupta V, Lim Z, Ho AY, Ireland RM, Hayden J et al. Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia. Blood 2011; 118: 2351–2357.
Malladi RK, Peniket AJ, Littlewood TJ, Towlson KE, Pearce R, Yin J et al. Alemtuzumab markedly reduces chronic GVHD without affecting overall survival in reduced-intensity conditioning sibling allo-SCT for adults with AML. Bone Marrow Transplant 2009; 43: 709–715.
Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009; 10: 855–864.
Schattenberg A, van der Meer A, Preijers F, Schaap N, Rinkes M, van der Maazen R et al. Addition of ATG to the conditioning regimen is a major determinant for outcome after transplantation with partially lymphocyte-depleted grafts from voluntary unrelated donors. Bone Marrow Transplant 2004; 33: 1115–1121.
Bacigalupo A, Lamparelli T, Barisione G, Bruzzi P, Guidi S, Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 2006; 12: 560–565.
Socie G, Schmoor C, Bethge WA, Ottinger HD, Stelljes M, Zander AR et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood 2011; 117: 6375–6382.
Hoegh-Petersen M, Amin MA, Liu Y, Ugarte-Torres A, Williamson TS, Podgorny PJ et al. Anti-thymocyte globulins capable of binding to T and B cells reduce graft-vs-host disease without increasing relapse. Bone Marrow Transplant 2013; 48: 105–114.
Levine JE, Paczesny S, Sarantopoulos S . Clinical applications for biomarkers of acute and chronic graft-versus-host disease. Biol Blood Marrow Transplant 2012; 18 (1 Suppl): S116–S124.
Flowers MED, Inamoto Y, Carpenter PA, Lee SJ, Kiem HP, Petersdorf EW et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood 2011; 117: 3214–3219.
Rozmus J, Schultz KR . Biomarkers in chronic graft-versus-host disease. Expert Rev Hematol 2011; 4: 329–342.
Bacigalupo A, Lamparelli T, Milone G, Sormani MP, Ciceri F, Peccatori J et al. Pre-emptive treatment of acute GVHD: a randomized multicenter trial of rabbit anti-thymocyte globulin, given on day+7 after alternative donor transplants. Bone Marrow Transplant 2010; 45: 385–391.
Paczesny S, Krijanovski OI, Braun TM, Choi SW, Clouthier SG, Kuick R et al. A biomarker panel for acute graft-versus-host disease. Blood 2009; 113: 273–278.
Thiant S, Yakoub-Agha I, Magro L, Trauet J, Coiteux V, Jouet JP et al. Plasma levels of IL-7 and IL-15 in the first month after myeloablative BMT are predictive biomarkers of both acute GVHD and relapse. Bone Marrow Transplant 2010; 45: 1546–1552.
Cho B-S, Min C-K, Kim H-J, Lee S, Kim YJ, Lim JY et al. High levels of B cell activating factor during the peritransplantation period are associated with a reduced incidence of acute graft-versus-host disease following myeloablative allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2010; 16: 629–638.
Thiant S, Labalette M, Trauet J, Coiteux V, de Berranger E, Dessaint JP et al. Plasma levels of IL-7 and IL-15 after reduced intensity conditioned allo-SCT and relationship to acute GVHD. Bone Marrow Transplant 2011; 46: 1374–1381.
Toubai T, Tanaka J, Paczesny S, Shono Y, Reddy P, Imamura M . Role of cytokines in the pathophysiology of acute graft-versus-host disease (GVHD)- Are serum/plasma cytokines potential biomarkers for diagnosis of acute GVHD following allogeneic hematopoietic cell transplantation (allo-HCT)? Curr Stem Cell Res Ther 2012; 7: 229–239.
Sarantopoulos S, Stevenson KE, Kim HT, Cutler CS, Bhuiya NS, Schowalter M et al. Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood 2009; 113: 3865–3874.
Fujii H, Cuvelier G, She K, Aslanian S, Shimizu H, Kariminia A et al. Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children’s Oncology Group. Blood 2008; 111: 3276–3285.
Kobayashi S, Imamura M, Hashino S, Tanaka J, Asaka M . Clinical relevance of serum soluble interleukin-2 receptor levels in acute and chronic graft-versus-host disease. Leuk Lymphoma 1997; 28: 159–169.
Liem LM, van Houwelingen HC, Goulmy E . Serum cytokine levels after HLA-identical bone marrow transplantation. Transplantation 1998; 66: 863–871.
Sormani MP, Oneto R, Bruno B, Fiorone M, Lamparelli T, Gualandi F et al. A revised day +7 predictive score for transplant-related mortality: serum cholinesterase, total protein, blood urea nitrogen, [gamma] glutamyl transferase, donor type and cell dose. Bone Marrow Transplant 2003; 32: 205–211.
Podgorny PJ, Ugarte-Torres A, Liu Y, Williamson TS, Russell JA, Storek J . High rabbit-antihuman thymocyte globulin levels are associated with low likelihood of graft-vs-host disease and high likelihood of posttransplant lymphoproliferative disorder. Biol Blood Marrow Transplant 2010; 16: 915–926.
Remberger M, Sundberg B . Low serum levels of total rabbit-IgG is associated with acute graft-versus-host disease after unrelated donor hematopoietic stem cell transplantation: results from a prospective study. Biol Blood Marrow Transplant 2009; 15: 996–999.
Horowitz M, Gale R, Sondel PM, Goldman JM, Kersey J, Kolb HJ et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555–562.
Signori A, Crocchiolo R, Oneto R, Sacchi N, Sormani MP, Fagioli F et al. Chronic GVHD is associated with inferior relapse risk irrespective of stem cell source among patients receiving transplantation from unrelated donors. Bone Marrow Transplant 2012; 47: 1474–1478.
Jakobisiak M, Golab J, Lasek W . Interleukin 15 as a promising candidate for tumor immunotherapy. Cytokine Growth Factor Rev 2011; 22: 99–108.
Di Sabatino A, Calarota SA, Vidali F, Macdonald TT, Corazza GR . Role of IL-15 in immune-mediated and infectious diseases. Cytokine Growth Factor Rev 2011; 22: 19–33.
Bosch M, Dhadda M, Hoegh-Petersen M, Liu Y, Hagel LM, Podgorny P et al. Immune reconstitution after antithymocyte globulin-conditioned hematopoietic cell transplantation. Cytotherapy 2012; 14: 1258–1275.
Kinter AL, Godbout EJ, McNally JP, Sereti I, Roby GA, O’Shea MA et al. The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol 2008; 181: 6738–6746.
Yang J, Riella LV, Chock S, Liu T, Zhao X, Yuan X et al. The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo. J Immunol 2011; 187: 1113–1119.
Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097–2100.
Shlomchik WD, Couzens MS, Tang CB, Tang CB, McNiff J, Robert ME et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999; 285: 412–415.
Chen G, Wu D, Wang Y, Cen J, Feng Y, Sun A et al. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation. Eur J Haematol 2008; 81: 226–235.
Deeg HJ, Storer BE, Boeckh M, Martin PJ, McCune JS, Myerson D et al. Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. Biol Blood Marrow Transplant 2006; 12: 573–584.
Soiffer RJ, Lerademacher J, Ho V, Kan F, Artz A, Champlin RE et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 2011; 117: 6963–6970.
Devillier R, Crocchiolo R, Castagna L, Fürst S, El Cheikh J, Faucher C et al. The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT. Bone Marrow Transplant 2012; 47: 639–645.
Acknowledgements
The authors would like to thank the patients for participating in research that could not benefit them but only future patients. This study could not happen without the dedication of Polly Louie, Lynne Fisk, Judy Wu, Glennis Doiron, Feng Zhou, Monja Metcalf, as well as the staff of the Alberta Blood and Marrow Transplant Program, including inpatient and outpatient nurses (lead by Lorraine Harrison, Joanne Leavitt and Naree Ager), and physicians, including Drs Nancy Zacarias, Ping Yue, Nizar Bahlis, Chris Brown, Peter Duggan, Michelle Geddes, Lynn Savoie, Mona Shafey, Loree Larratt, and Robert Turner. This work was funded by Genzyme/Sanofi (JS, JAR, DR and AG), Alberta Heritage Foundation for Medical Research, Canada Research Chair Program and Alberta Cancer Foundation.
Author contributions: LMP performed the ELISA assays and wrote the manuscript. YL established the ELISA assays and supervised their conduct. AUT and MHP reviewed charts for patient outcomes. PJP measured ATG levels. AWL facilitated determinations of γ-glutamyl transpeptidase, urea, total protein and cholinesterase. TSW lead statistical analyses. JAR, AG and DR critically reviewed the manuscript. JS designed the study, supervised its conduct and extensively edited the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on Bone Marrow Transplantation website
Supplementary information
Rights and permissions
About this article
Cite this article
Pratt, L., Liu, Y., Ugarte-Torres, A. et al. IL15 levels on day 7 after hematopoietic cell transplantation predict chronic GVHD. Bone Marrow Transplant 48, 722–728 (2013). https://doi.org/10.1038/bmt.2012.210
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2012.210
Keywords
This article is cited by
-
The Role of NK Cells and Their Exosomes in Graft Versus Host Disease and Graft Versus Leukemia
Stem Cell Reviews and Reports (2023)
-
Polymorphisms in CXCR3 ligands predict early CXCL9 recovery and severe chronic GVHD
Blood Cancer Journal (2021)
-
Biologic markers of chronic GVHD
Bone Marrow Transplantation (2014)